Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-01-04
2005-01-04
Canella, Karen A. (Department: 1642)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S328000, C435S334000, C435S343100, C536S023530
Reexamination Certificate
active
06838261
ABSTRACT:
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
REFERENCES:
patent: 5182368 (1993-01-01), Ledbetter et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5597569 (1997-01-01), Siegall et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5872215 (1999-02-01), Osbourne et al.
patent: 5874082 (1999-02-01), de Boer
patent: 6056959 (2000-05-01), de Boer et al.
patent: WO 9618413 (1996-06-01), None
Clark, Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, pp. 4-5.*
Abstract of Charreau et al (Transgene Research, 1996, vol. 5, pp. 223-234).*
Abstract of Nancarrow et al (Methods in Molecular Biology, 1993, vol. 18, pp. 273-303).*
Abstract of Machaty et al (Cloning Stem Cells, 2002, vol. 4, pp. 21-27).*
Braesch-Anderson et al, Journal of Immunological Methods, 1986, vol. 94, pp. 145-151.*
Accession No. S69899, Feb. 14, 1997.*
Accession No. A61522, Oct. 15, 1994.*
Accession No. D50136, Apr. 12, 1995.*
Accession No. W78434, 1998, Antibody light chain directed to HER3 clone 18.
Accession No. Y06716, 1999, Antibody 12B5 single chain Fv (scFv) fragment.
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. S69899, 1997, Ig heavy chain V region (clone RFTS7H), rheumatoid factor—human.
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. S67941, 1997, Ig heavy chain variable region, subgroup I (clone MH52)—human (fragment).
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. C29380, 1988, Ig kappa chain precursor V region (BC-1004)—mouse (fragment).
Allessandrini and Desiderio, “Coordination of Immunoglobulin DJHTranscription and D-to-JHRearrangement by Promoter-Enhancer Approximation,” Molecular Biology, 1991, 11(4):2096-2107.
Armitage et al., “Distinct patterns of inhibition by CD40 mAb of the CD40 ligand-CD40 interaction,” inLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1: 551-552.
Bjorck and Paulie, “CD40 Antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation,” Immunology, 1996, 97, 291-295.
Bjorck et al., “Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40,” 1994, 83, 430-437.
Bubenik J et al., “Monoclonal antibodies against human urinary bladder carcinomas: selectivity and utilization for gamma scintigraphy,” Eur J Cancer Clin Oncol. Jun. 1985;21(6):701-10.
Challa A et al., “Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells,” Allergy. Jun. 1999;54(6):576-83.
Chen et al., “Nucleotide and translated amino acid sequences of cDNA coding for the variable regions of the light and heavy chains of mouse hybridoma antibodies to blood group A and B substances,” Journal of Biological Chemistry, 1987, 282(28):13579-13583.
Clark EA and Ledbetter JA, “Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50,” Proc Natl Acad Sci U S A. Jun. 1986;83(12):4494-8.
De Paoli P, “High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants,” Cytometry. Feb. 15, 1997;30(1):33-8.
Fanslow et al., “CD40 mAb M2 and M3 inhibit CD40 ligand binding and function,”Leukocyte Typing V, Schlossman et al. (Eds.) 1995; 1: 555-556.
Francisco JA et al., “Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1,” J Biol Chem. Sep. 26, 1997;272(39):24165-9.
Frisch et al., “A soluble immunoglobulin variable domain without a disulfide bridge: construction, accumulation in the ctoplasm ofE. coli, purification and physicochemical characterization,” Biol. Chem, 1994, 375: 353-356.
Funakoshi S et al., “Inhibitioin of human B-cell lymphoma growth by CD40 stimulation,” Blood. May 15, 1994; 83(10):2787-94.
Funakoshi S et al., “Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas,” J Immunother Emphasis Tumor Immunol. Mar. 1996;19(2):93-101.
Gilliland LK et al., “Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments,” Tissue Antigens. Jan. 1996;47(1):1-20.
Grafton G et al., “Mechanisms of antigen receptor-dependent apoptosis of human B lymphoma cells probed with a panel of 27 monoclonal antibodies,” Cell Immunol. Nov. 25, 1997;182(1):45-56.
Grewal IS and Flavell RA, “CD40 and CD154 in cell-mediated immunity,” Annu Rev Immunol. 1998;16:111-35.
Herbert and Callard, “Inhibition of specific antibody production by CD40L and a panel of antibodies to CD40,” inLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1:552-554.
Katira et al., “CD40 Workshop Panel report,” inLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1: 547-550.
Katira et al., “Identification of co-operative epitopes on CD40 supports the existence of a second CD40 ligand,” inLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1: 554.
Kawabe et al., “Generation and characterization of CD40-deficient mice,”Leukocyte Typing V, Schlossman et al. (Eds.) 1995; 1: 550-551.
Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death, J Immunol. Apr. 1, 1996;156(7):2345-8.
Kim et al., “Restoring allosterism with compensatory mutations in hemoglobin,” Proc. Natl. Acad. Sci. USA, 1994, 91: 11547-11551.
Koho H et al., “Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence,” Cancer Immunol Immunother. 1984;17(3):165-72.
Kuhne MR et al., “Assembly and regulation of the CD40 receptor complex in human B cells,” J Exp Med. Jul. 21, 1997; 186(2):337-42.
Kwekkeboom et al., “CD-40 plays an essential role in the activation of human B cells by murine EL4B5 cells,” Immunology, 1993, 79: 439-444.
Malik N et al., “Activation of human monocytes through CD40 induces matrix metalloproteinases,” J Immunol. May 15, 1996; 156(10):3952-60.
Mathews and van Holde, Biochemistry, 2nd Edition, 1995, pp. 165-171.
Matthews BW, “Genetic and structural analysis of the protein stability problem,” In: Perspectives in Biochemistry, 1989, chapter 2, pp. 6-9.
Murphy WJ et al., “Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes,” Blood. Sep. 1, 1995;86(5):1946-53.
Noelle RJ et al., “A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells,” Proc Natl Acad Sci U S A. Jul. 15, 1992;89(14):6550-4.
Paulie S et al., “The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction,” J Immunol. Jan. 15, 1989;142(2):590-5.
Pound JD et al, “Minimal cross-linking and epitope requirements for CD40-dependent suppr
Fell, Jr. Henry Perry
Francisco Joseph A.
Siegall Clay B.
Wahl Alan F.
Canella Karen A.
Conforti Vita G.
Day Jones
Seattle Genetics Inc.
LandOfFree
Nucleic acids encoding anti-CD40 proteins and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding anti-CD40 proteins and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding anti-CD40 proteins and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3438253